Dopamine D3 Receptors: From Bench to Bedside.

Area of Science:

• Neuropharmacology
• Molecular Psychiatry

Background:

• Dopamine D3 receptors are part of the D2-like family, with specific distribution in brain areas relevant to antipsychotic and Parkinson's disease medications.
• Dopamine D3 receptors are implicated in various neurological and psychiatric conditions.

Purpose of the Study:

• To explore the role of dopamine D3 receptors in psychiatric and neurological disorders.
• To highlight the therapeutic potential of D3 receptor-targeting drugs, exemplified by cariprazine.

Main Methods:

• Review of preclinical studies and clinical trials on cariprazine.
• Analysis of D3 receptor pharmacology and its implications in disease states.

Main Results:

• Cariprazine, a D2/D3 partial agonist with D3 preference, demonstrated clinical benefits in schizophrenia and bipolar disorder.
• Cariprazine is the first antipsychotic approved for manic, mixed, and depressive bipolar I disorder episodes.
• D3 receptor antagonism may alleviate levodopa-induced dyskinesia and psychosis in Parkinson's disease.

Conclusions:

• Dopamine D3 receptors are promising therapeutic targets for psychiatric and neurological disorders.
• Cariprazine exemplifies the successful development of D3 receptor-targeting agents.
• Further research into D3 receptor modulation could lead to improved treatments for CNS disorders.